Linda West - 28 May 2021 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Role: Director
Signature: /s/ Chris Degnan, Attorney-in-Fact for Linda West
Issuer symbol: GRTX
Transactions as of: 28 May 2021
Net transactions value: +$172,791
Form type: 4
Filing time: 02 Jun 2021, 17:35:11 UTC
Next filing: 04 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GRTX	Common Stock	Purchase	$86,410	+10,000		$8.64^*	10,000	28 May 2021	Direct	F1
transaction	GRTX	Common Stock	Purchase	$86,381	+10,000	+100%	$8.64^*	20,000	01 Jun 2021	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.59 to $8.6759, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.59 to $8.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.59 to $8.6759, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.59 to $8.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.